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MetalloproteinaseThe present study aimed to investigate the effects of MBZ on a humanmalignant ascites cell line derived from a
primary gastric cancer tumor. Our data reveal that MBZ showed high cytotoxicity in vitro, displaying an IC50 of
0.39 μM and 1.25 μM in ACP-02 and ACP-03, respectively. The association between MBZ and 5-FU increased
slightly the cytotoxicity when compared to MBZ and 5-FU alone. Furthermore, MBZ disrupted the microtubule
structure of AGP-01 cells and inhibited signiﬁcantly the invasion and migration of these cells. Activity of active
MMP-2 signiﬁcantly decreased at all tested concentration of MBZ compared to negative control. These results
support the indication of MBZ in combination with chemotherapeutic agents as a possible adjuvant therapy for
themanagement/treatment of patients with advanced gastric cancer sinceMBZ is a drug of low cost with accept-
able safety proﬁle and reduced toxicity to normal cells. However, clinical trialsmust be performed in o to evaluate
its efﬁcacy in gastric cancer patients.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Gastric cancer (GC) is the fourth most common cancer and the
second leading cause of cancer-related death in the world (Jemal
et al., 2011). Two thirds of patients with gastric cancer have locally
advanced or metastatic disease at diagnosis, generally owing to the ab-
sence of speciﬁc symptoms that renders early diagnosis of this disease
difﬁculty (Catalano et al., 2005). Up to one half of patients have recur-
rent disease after curative surgery, and the outcomes for these patients
are still very poor, with an estimated 5-year survival rate in only 20% of
the patients (Hohenberger and Gretschel, 2003; Kamangar et al., 2006;
Yoong et al., 2011).
Peritoneal carcinomatosis (PC) or malignant ascites (MA) is deﬁned
by theNational Cancer Institute (NCI) fromU.S. as “a condition inwhich
ﬂuid containing cancer cells collects in the abdomen” and represents an
advanced state of several types of cancer, especially in gastric cancer
(Chung and Kozuch, 2008). There is a lack of randomized controlled
trials identifying the most favorable therapy, mainly because PC is
highly resistant to the current therapeutics in clinics, and therefore
evidence-based therapeutic guidelines have not been established
yet (Sugiyama et al., 2011). Taking all together, there is an urgentntenegro).need to introduce new therapeutic agents in themanagement of perito-
neal carcinomatosis.
Mebendazole (MBZ), methyl N-[6-(benzoyl)-1H-benzimidazol-2-
yl] carbamate, an approved drug by the US Food and Drug Administra-
tion (FDA), is available for treating roundworm (Ascaris lumbricoides),
common hookworm (Ancylostoma duodenale), American hookworm
(Necator americanus), pinworm (Enterobius vermicularis), and
whipworm (Trichuris trichiura) in humans and animals, acting by
depolymerizing tubulin and thus disrupting the functions of microtu-
bules (El-On, 2003; Messaritakis et al., 1991; Munst et al., 1980; Vutova
et al., 1999). Moreover, MBZ has been proved to inhibit the growth of
different cancer cells in vitro and in vivo (Bai et al., 2011; Doudican
et al., 2008; Martarelli et al., 2008; Mukhopadhyay et al., 2002). The
mechanism of action for MBZ and other benzimidazoles is to bind to
the tubulin subunits in the gut epithelium of the parasite, preventing po-
lymerization of the tubulin, causing ultrastructural changes, and eventu-
ally preventing parasite growth (Kohler, 2001; MacDonald et al., 2004).
Tubulin is vital to cell division and is also a cancer target for several che-
motherapy drugs, including paclitaxel, colchicine, and vincristine (Bai
et al., 2011).
Based upon these ﬁndings and the clinically proved safety of
MBZ (Janssen Inc., 2014; Lacey, 1988; Sajid et al., 2006; Van der
Westhuizen et al., 1984) this work analyzed the effects of MBZ on a
humanmalignant ascites cell line derived from a primary gastric cancer
tumor.
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2.1. Ethics statement
All samples were derived with written informed consent and
approval from the University Hospital (Belém, Pará, Brazil) ethical
review boards (protocol number: 142004).
2.2. Gastric cancer cells (GC)
Our group established and characterized cytogenetically three new
GC cell lines obtained from primary gastric adenocarcinoma (ACP-02,
diffuse type and ACP-03, intestinal type) from two different patients
and an ascitic ﬂuid (AGP-01, malignant ascites) from a patient with
primary tumor on stomach (Intestinal-type adenocarcinoma), each of
which exhibited a composite karyotype with several clonal chromo-
some alterations similar to the respective primary tumor from the
stomach as described previously (Leal et al., 2009). All cell lines were
maintained in DMEM medium supplemented with 10% fetal bovine
serum, 2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL strepto-
mycin at 37 °C with 5% CO.
2.3. Chemicals
MBZ (Medley® 500mg, source 81G6I5V05I) was dissolved in DMSO
to a concentration of 10 mg/mL and stored at−20 °C as a master stock
solution. Paclitaxel (6 mg/mL) was purchased from Bristol-Myers
Squibb Company (Princeton, NJ), 5-ﬂuororacil (2.5 mg/mL), oxaliplatin
(5 mg/mL), gencitabin (40 mg/mL) and irinotecan (20 mg/mL)
were purchased fromGenlibbs®, doxorubicin (100 μg/mL) and cisplatin
(5 mg/mL) were purchased from Sigma®, and etoposide (20 mg/mL)
was purchased from Pﬁzer®.
2.4. Cytotoxicity against cancer cell lines
MBZ (0.15–20 μM) were tested for cytotoxic activity against three
cancer cell lines: ACP-02 (diffuse-type adenocarcinoma), ACP-03
(intestinal-type adenocarcinoma) and AGP-01 (malignant ascites).
Each compound was dissolved with DMSO and diluted with media to
obtain a concentration of 20 μM. They were incubated with the cells
for 72 h. The negative control received the same amount of DMSO
(0.005% in the highest concentration). Doxorubicin was used as a posi-
tive control of cytotoxicity in MTT assay. The cell viability was deter-
mined by reduction of the yellow dye 3-(4,5-dimethyl-2-thiazol)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) to a blue formazan product
after 72 h as described previously (Mosmann, 1983). Drug effect was
quantiﬁed as the percentage of control absorbance of reduced dye at
550 nm.
The following experiments were performed in AGP-01 cell line and
the concentrations used for MBZ (0.1 μM, 0.5 μM and 1.0 μM) were
based on its IC50 after 72 h.
2.5. Immunoﬂuorescence staining
Cells (5 × 103/well) were grown on a glass chamber slide and
treated with 0.005% of DMSO, 0.1 μM of colchicine, 1.0 μM of paclitaxel,
0.1 μM, 0.5 μMand 1.0 μMofMBZ for 14 h and then ﬁxed for 1 h at room
temperature with 4% paraformaldehyde solution as previously de-
scribed by (Doudican et al., 2008). Paclitaxel (1 μM) and colchicine
(0.1 μM) were used as a positive control of tubulin inhibition in immu-
noﬂuorescence staining. They were then washed with PBS and perme-
abilized with PBS and Triton 0.2% for 20 min. Cells were ﬁrst blocked
by 5% bovine serum albumin (BSA) in PBS for 30 min at room tempera-
ture and incubated with monoclonal mouse anti-α-tubulin antibody
(Sigma)with 1% BSA overnight on 4 °C. This was followed by incubation
with Alexa Fluor®488 for 1 h. They were then washed 3 times with PBSin between and after the process. After staining, the slideswere covered
with mounting medium containing DAPI (Roche Diagnostics) and
examined on a ﬂuorescence microscope (Olympus, Tokyo, Japan).
2.6. Trypan blue exclusion
Cell doubling time of AGP-01 was also determined by this assay
(Louis and Siegel, 2011). Cells were seeded into 24-well plates at a
density of 2 × 104 cells per well and were incubated for 12 h at 37 °C.
After 12 h, aliquots from each well were removed from the cultures in
0 h and after 3 h, 6 h, 12 h, 24 h, 27 h and 30 h of incubation, stained
with 0.4% trypan blue and counted in a Neubauer chamber. The staining
was used to quantify the number of living cells in the samples. Experi-
ments were performed in triplicate.
Cell viability was also determined by trypan blue assay (Louis and
Siegel, 2011). Cells were seeded in a 12-well plates at a density
of 4 × 104 cells per well. After 24 h, they were treated with MBZ at
0.1 μM, 0.5 μM and 1.0 μM. Aliquots from each well were removed
from the cultures after 14 h of treatment to demonstrate that the expo-
sure time of MBZ has no cytotoxicity for the cell invasion assay.
2.7. Wound healing assay
In vitro wound healing assay was performed to evaluate the migra-
tion of cells (Liang et al., 2007). Cells were seeded into 12-well plates at
a density of 1 × 105 cells per well for 24 h at 37 °C. After the growing cell
layers had reached conﬂuence, wounds were prepared by a single
scratch on the monolayer using a white pipette tip and washed with
PBS to remove cell debris. Cells were treated with MBZ at concentra-
tions (0.1 μM, 0.5 μM and 1.0 μM) in triplicate for 14 h. The areas be-
tween the edges of the scratches were quantiﬁed at different times
(0 h, 6 h, 12 h and 24 h) using the Image J program.
2.8. Matrigel invasion assay
In vitro invasion assay was performed using modiﬁed Boyden
chamber with ﬁlter inserts (8-μm pores) for 6-well plates (BD Biosci-
ences, San Jose, CA, USA) (Albini et al., 1987). The upper surfaces of
the membranes were coated with Matrigel (BD Biosciences, San Jose,
CA, USA) and incubated at 37 °C overnight. Cells were treated with
MBZ (0.1 μM, 0.5 μM and 1.0 μM) for 14 h. After, cells (2.5 × 105/mL)
was added to each well with serum-free culture medium and lower
chamber was ﬁlled with 2.8 mL of medium containing 10% FBS for
10 h. Cells were washed 3 times in PBS in between and then stained
with giemsa. The non-invading cells were removed using a cotton
swab and the numbers of invasive cells were then counted in seven
random ﬁelds of the insert. Experiments were performed in triplicate.
2.9. Gelatin zymography
Cells were seeded into 6-well plates at a density of 2 × 105 per well
for 24 h at 37 °C. Cells were treated with MBZ (0.1 μM, 0.5 μM and
1.0 μM) with serum-free culture medium for 14 h. HT1080 cells were
used as a positive control. Protein concentration was determined by
using Bradford Reagent (Serva).
Proteins (25 μg/mL) were separated in gel SDS-PAGE 10%
copolymerized with gelatin 10% (Sigma-Aldrich) (Troeberg and
Nagase, 2004). Electrophoresis was carried out using the minigel slab
apparatus Mini Protean 3 (Biorad) at initial voltage of 90 V in stacking
gel, after constant voltage of 100 V, until the dye reached the bottom
of the gel. Following electrophoresis, gels were washed 4 times in rena-
turation buffer (2.5% Triton X-100) for 15min in an orbital shaker. Then
the zymograms were incubated for 18 h at 37 °C in incubation buffer
(50 mM M Tris, 10 mM CaCl2, 50 mM ZnCl). Gels were then stained
with Coomassie blue and destained with methanol, acetic acid and
water (4.5:1:4.5). Areas of enzymatic activity appeared as clear bands
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using the area of the band selection and analyzed using Image J program
that is capable of quantifying the optical density of each pixel, using the
bottom of the gel as a blank (Xueyou and Christine, 2010). Experiments
were carried out in triplicates.
2.10. Statistical analyses
Data obtained from different experiments are presented as mean ±
SEM from at least three independent experiments in triplicate and
evaluated by analysis of variance (ANOVA) followed by Tukey test and
Bonferroni test using a signiﬁcance level of 5%.
3. Results
3.1. MBZ inhibits the proliferation of gastric cancer cells
All gastric cancer cell lines were treated with increasing concentra-
tions of MBZ (0.15–20 μM) and well-known clinical chemotherapeutics
for 72 h and analyzed by MTT assay. A signiﬁcant suppression of cell
growth was observed in the presence of MBZ (Table 1).
MBZ was more potent against diffuse type gastric cancer cell line
(ACP-02) (IC50 0.39 μM) than the other well-known chemotherapeutic
drugs used in clinics as 5-FU (IC50 19.71 μM), oxaliplatin (IC50 8.85 μM),
gemcitabine (IC50 7.47 μM), irinotecan (IC50 29.83 μM), paclitaxel (IC50
2.43 μM) cisplatin (IC50 15.82 μM) and doxorubicin (IC50 0.82 μM).
As for intestinal type gastric cancer cell line (ACP-03) the IC50 was
1.25 μM, being 3 times more resistant to MBZ than diffuse type gastric
cancer cell line (ACP-02). MBZ is still more potent than the current
chemotherapeutic drugs used in clinics such as oxaliplatin, irinotecan,
etoposide and cisplatin (Table 1).
Malignant ascites cell line (AGP-01) derived from a primary intesti-
nal type gastric cancer, showed IC50 of 0.59 μM forMBZ, which ismainly
half of the IC50 observed for ACP-03 (IC50 1.25 μM) which is a primary
intestinal-type gastric cancer cell line. MBZ also presented similar
activity to 5-FU (IC50 0.67 μM) and paclitaxel (IC50 0.62 μM) and showed
higher activity in AGP-01 cells when compared with oxaliplatin (IC50
4.77 μM), irinotecan (IC50 41.10 μM), etoposide (IC50 10.31 μM) and
cisplatin (IC50 17.23 μM). The association between MBZ and 5FU
increased slightly the cytotoxicity when compared to MBZ and 5-FU
alone. However, they are not statistically different.Table 1
In vitro cytotoxic activity ofMBZ. IC50 values (μM)and conﬁdence interval of 95% obtained by th
three independent experiments in triplicate.
IC50 (μM)
ACP-02
Mebendazole 0.39
(0.26–0.59)
5-Fluororacil 19.71
(15.68–24.78)
Oxaliplatin 8.85
(6.40–12.22)
Gemcitabine 7.47
(5.05–11.04)
Irinotecan 29.83
(25.26–35.23)
Etoposide 0.20
(0.10–0.38)
Paclitaxel 2.43
(2.24–2.64)
Cisplatin 15.82
(12.78–19.58)
Doxorubicin 0.82
(0.63–1.07)
Mebendazole + 5FU ND
ND: not determined; 5-FU: 5-ﬂuororacil.The association between MBZ and 5-FU demonstrates a decrease in
toxicity (IC50 0.38 μM) (Table 1). Our results showedMBZ as a potential
candidate in the chemotherapy regiments for malignant ascites.
3.2. MBZ disrupts the microtubule structure of AGP-01 cells
The effects of MBZ on microtubule formation in AGP-01 cells were
directly assessed through immunoﬂuorescence microscopy (Fig. 1).
After treatment with MBZ 0.1, 0.5 and 1.0 μM for 14 h, we observed
overall microtubular network disarray characterized by diffuse staining
(Fig. 1D, E and F). Paclitaxel and colchicine were used as a positive
control, showing a similar effect (Fig. 1B and C). In contrast, Fig. 1A
shows that vehicle-treated malignant ascites cells display discrete
networks of microtubule structure.
3.3. MBZ suppresses the migration and invasion of AGP-01 cells
We ﬁrst ensured that the inhibition of invasion was not due to cell
death. Thus, the viability of AGP-01 cells was assessed after 14 h of
treatment with 0.1, 0.5 and 1.0 μM of MBZ. The results indicated that
MBZ did not alter the viability of AGP-01 cells in all tested concen-
trations after 14 h of treatment (Fig. 2E). Thus, MBZ signiﬁcantly
inhibited invasion at concentration of 0.1 μM (p b 0.0005), 0.5 μM and
1.0 μM (p b 0.0001) (Fig. 2F), as shown in cells untreated (Fig. 2A) or
treated with MBZ 0.1 μM (Fig. 2B), 0.5 μM (Fig. 2C), 1.0 μM (Fig. 2D).
These ﬁndings were further conﬁrmed by the wound healing assay.
For this, we previously established cell-doubling time to avoid prolifer-
ation interference. In this assay, viable cells were quantiﬁedwith trypan
blue dye at the times 0 h, 3 h, 6 h, 12 h, 24 h, 27 h and 30 h and observed
that the cells doubled approximately after 24 h (Fig. 3A). Thus, MBZ
signiﬁcantly decreased migration at 0.5 μM (p b 0.01) and 1.0 μM
(p b 0.05) after 12 h of treatment and at 0.1 μM (p b 0.01), 0.5 μM (p b
0.001) and 1.0 μM (p b 0.001) after 24 h of treatment as shown in
Fig. 3B and C.
3.4. MBZ decreases metalloproteinase 2 activity in AGP-01
Zymographywas performed to determineMMP-2 andMMP-9 activ-
ities in all tested concentrations ofMBZ after 14 h of treatment (Fig. 4A).
As shown in Fig. 4B and C, no inhibition was observed for MMP-9
inactive andMMP-9 active in all tested concentrations of MBZ comparedeMTT assay in gastric cancer cell lines after 72 of exposure. Experimentswere performed in
ACP-03 AGP-01
1.25
(1.04–1.51)
0.59
(0.44–0.79)
0.38
(0.30–0.49)
0.67
(0.53–0.86)
1.88
(1.58–2.23)
4.77
(4.18–5.44)
0.21
(0.19–0.22)
0.02
(0.003–0.16)
32.07
(26.73–38.47)
41.10
(31.06–54.38)
18.47
(14.29–23.87)
10.31
(8.01–13.27)
0.99
(0.64–1.55)
0.62
(0.51–0.76)
28.62
(23.43–34.99)
17.23
(12.69–23.38)
0.23
(0.18–0.29)
0.25
(0.19–0.33)
ND 0.38
(0.24–0.62)
Fig. 1.Mebendazole (MBZ) induces disruption of microtubules in AGP-01 cells. Cells were untreated (A) or treated with paclitaxel 1 μM (B), colchicine 0.1 μM (C) and MBZ 0.1 μM (D),
0.5 μM (E), and 1.0 μM (F) after 14 h of treatment and examined by ﬂuorescent microscopy (40×). Analyses were performed in three independent experiments with two biological
replicates.
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of MMP-2 active in all tested concentrations compared to negative
control (p b 0.0001) (Fig. 4D). HT1080 was used as a positive control
for metalloproteinase activity.4. Discussion
Herein, we described MBZ as a potentially effective agent in the
treatment/management of malignant ascites tumors derived from
gastric cancer. In recent years, gastric cancer patients have been treated
with 5-FU/cisplatin, however additional drugs were introduced in
chemotherapy regimens such as oxaliplatin, irinotecan and taxanes.
The results of phase II studies showed a promising efﬁcacy andmanage-
able toxicity proﬁle for combination chemotherapy, including theseFig. 2.Mebendazole (MBZ) signiﬁcantly inhibited invasion in AGP-01 cells. Cells were untreated
AGP-01 cells viability after 14 h of treatment with MBZ in trypan blue assay. The bars represen
Cell invasion assay after 14 h of treatment with MBZ in three concentrations. The bars repre
(F). *p b 0.0005, **p b 0.0001 compared with the negative control by ANOVA followed by Tukenew substances (Al-Batran et al., 2004; Bouche et al., 2004; Chao et al.,
2004).
In phase III study, Kim et al. (1993) reported an overall response rate
of 51% and an overall survival with a median of 9.0 months for regimen
5-FU/cisplatin in gastric in previously untreated patients with advanced
gastric cancer. First-line chemotherapy with paclitaxel/cisplatin also
showed response rates of 44–46% and a median overall survival of
11.2 to 13.8 months (Kornek et al., 2002; Park et al., 2004; Lee et al.,
2005). Efforts to improve the treatment of cancer have been a major
problem being a challenge to search for new chemotherapeutic agents
and combinations in an attempt to reduce acute toxicity and treatment
failure.
Our study demonstrated an increase in activity when MBZ is associ-
ated to 5-FU inmalignant ascites cell lines (AGP-01 cells). The toxicity of
5-FU is a serious and common problem formany cancer patientsmainly(A) or treatedwithMBZ 0.1 μM(B), 0.5 μM(C), and 1.0 μM(D) inmatrigel invasion assay.
t the mean ± standard error of mean of three independent experiments in triplicate (E).
sent the mean ± standard error of mean of three independent experiments in triplicate
y test.
Fig. 3.Mebendazole (MBZ) signiﬁcantly decreasedmigration inAGP-01 cells. Cell doubling time of AGP-01 cellsmonitored for 30 h. The bars represent themean± standard error ofmean
of three independent experiments (A). Microphotograph of cell migration assay after 24 h of treatment in three concentrations studied showing the areas of scratches (B). Values calcu-
lated of the areas of scratches cell migration assay after treatment with different concentrations of theMBZ. The bars represent the mean ± standard error of mean of three independent
experiments in triplicate (C) *: p b 0.05, **: p b 0.01, ***: p b 0.001 compared to negative control by 2-way ANOVA followed by Bonferroni test.
Fig. 4.Mebendazole (MBZ) signiﬁcantly decreased activity of MMP-2 active. Gel zymography of AGP-01 cells treated with MBZ concentrations 0.1 μM, 0.5 μM, and 1.0 μM (A). Inactive
MMP9 (B). Active MMP9 activity (C). Active MMP2 activity (D). Data was calculated from densitometry of the bands in the program Image J. Bars represent the mean ± standard
error of three independent experiments in triplicate. *p b 0.0001 compared with the negative control by ANOVA followed by Tukey test. HT1080 is used as a positive control. P: inactive.
A: active.
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commonly observed side effects (Saif et al., 2009). The clinical activity
of 5-FU is modest at normal used doses and, in general, treatment is
limited by safety proﬁle. Various strategies have been developed to in-
crease clinical efﬁcacy/safety of 5-FU, such as the biochemical modula-
tion (Leichman et al., 2002), changes in management schemes (Levi
et al., 1994) and the use of combination therapy (Aquino et al., 1998;
Melen-Mucha et al., 2004; Obi et al., 2006). In contrast, MBZ is orally
available and exhibits favorable pharmacokinetics, suggesting that this
drug deserves further investigation as anticancer agents because of
their potential in improving the efﬁcacy and remarkable safety proﬁle
to other drugs (Doudican et al., 2008).
This study demonstrates the anticancer effects of MBZ in malignant
ascites and agrees with previously reported studies in other types of
cancer cell lines (Bai et al., 2011; Doudican et al., 2008; Martarelli
et al., 2008;Mukhopadhyay et al., 2002).MBZ has shown preclinical an-
ticancer activity in vivo and in vitro in glioblastoma multiforme
(IC50 ~ 0.1 μM) (Bai et al., 2011), melanoma (IC50 = 0.32 μM)
(Doudican et al., 2008), adrenocortical carcinoma (IC50 = 0.23 μM)
(Martarelli et al., 2008), and lung cancer (IC50 = 0.16 μM)
(Mukhopadhyay et al., 2002). However, this is the ﬁrst study showing
the cytotoxic effects of MBZ in gastric cancer cell lines and inmalignant
ascites cells derived from a primary gastric adenocarcinoma showing an
IC50 lower than 1 μM.
Microtubules arewidely recognized as effective targets for anticancer
therapy. As key components of the cytoskeleton,microtubules are essen-
tial for cellular structure, intracellular transport, mitosis, and cell division
(Nogales, 2001). Several studies demonstrated cytoskeletal components
are involved in adhesive interactions during formation of distant tumor
metastasis (Haier et al., 1999; Kadi et al., 1998; Korb et al., 2004).
Microtubule-targeted drugs such as paclitaxel and Vinca alkaloids
exert their inhibitory effect on cancer cell proliferation primarily by
disrupting the mitotic spindle, causing cell cycle arrest at the meta-
phase–anaphase transition and inducing apoptosis (Jordan et al.,
1996; Yvon et al., 1999). The disruption of the balance between the
monomers/dimers and polymers of tubulin microtubules caused by
microtubule stabilizing agents (such as paclitaxel, docetaxel), or micro-
tubule destabilizing agents (e.g., vinblastine, vincristine, nocodazole,
colchicine) activates signaling cascades of stress-activated protein
kinases. Such disruption of microtubules is associated with the phase
lockG2-M (Bhalla et al., 1993; Horwitz, 1992; Long and Fairchild, 1994).
Our study demonstrated a disruption of microtubule structure in
AGP-01 cells treated with MBZ and the same results were observed in
glioblastoma multiforme cells (Bai et al., 2011) and in melanoma cells
(Doudican et al., 2008).
The progression ofmalignant cells results in the invasion andmetas-
tasis processes, which are directly involved in poor prognosis. The de-
velopment of peritoneal metastasis is a multistep process, beginning
with the detachment of cancer cells from the primary tumors, their at-
tachment to peritoneal mesothelial cells, retraction of the mesothelial
cells, and exposure of the basement membrane. After attachment to
the basement membrane, the cancer cells degrade the extracellular
matrix and proliferate (Yonemura et al., 1996). Finally, the cancer cells
induce angiogenesis and lymphangiogenesis. Many cytokines, adhesive
factors, growth factors, matrix metalloproteinases (MMPs), and angio-
genic factors play important roles in these steps. During this process,
several stages are involved as critical event such as cell motility and
invasiveness, which involves the interaction of tumor cells with the
extracellular matrix (Akiyama et al., 1995).
Degradation of the extracellular matrix is considered to be a pre-
requisite for metastasis, specially, for peritoneal metastasis, and
MMPs are thought to play an important role in this process (Nagase
and Woossner, 1999; Mizutani et al., 2000). There are many reports
showing that highly invasive cancer cells with a high potential for
metastasis stimulate the production of MMPs (Nagase and Woossner,
1999), and MMP-2 is signiﬁcantly correlated with depth of invasion,lymph node metastasis, and distant metastasis of gastric cancer
(Monig et al., 2001). Moreover, cadherin and MMPs are related to the
detachment of cancer cells from the gastric wall (Shimoyama and
Hirohashi, 1991; McDonnell et al., 1991). MBZwas effective in reducing
the activity of MMP-2 in the AGP-01 cells, suggesting its action in
inhibiting the invasion of cancer cells in vitro. This is the ﬁrst study
demonstrating the inhibition of matrix metalloproteinases activity
after treatment with MBZ.
Agents that can change any of the steps of themetastatic cascade has
become potential candidates for anticancer therapy due mainly in met-
astatic tumors where therapy is still ineffective (Da-Yong et al., 2014).
Our study showed that MBZ inhibited migration and invasion in malig-
nant ascites cells, and these results corroborate with Martarelli et al.
(2008) that shown that MBZ inhibited adrenocortical carcinoma cells
migration and invasion in vitro and metastasis formation in vivo
(Martarelli et al., 2008).
In summary, these initial results support the ﬁnding that MBZ is
effective alone or in combination with chemotherapeutic agents in
the management of advanced gastric cancer in vitro. Furthermore,
this is a drug of low cost with acceptable safety proﬁle, reduced tox-
icity to normal cells, and able to reduce the growth and themigration
and invasion of cancer cells in vitro and in vivo, however clinical tri-
als must be performed in order to evaluate its efﬁcacy in gastric can-
cer patients.
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